Ultragenyx Pharmaceutical Inc. (RARE) · Oct 14, 2026 · Disposition

Ultragenyx PRV sale adds $203M as FAYUVI launch begins

$203M PRV sale — $203M cash payable at closing

Ultragenyx’s PRV sale brings in $203 million of potential cash as newly approved FAYUVI moves toward commercialization, subject to closing.

Ultragenyx is moving from rare-disease development into commercialization, with newly approved FAYUVI positioned as the first FDA-approved treatment for Sanfilippo syndrome Type A and commercial shipments expected within 30–60 days. This filing monetizes a non-core regulatory asset while that launch gets underway. The company agreed to sell the Rare Pediatric Disease Priority Review Voucher earned with FAYUVI approval for $203 million in cash.

The cash is incremental funding, not operating revenue. It gives Ultragenyx additional non-dilutive capital during a period when it is launching FAYUVI and advancing a broader rare-disease pipeline, but the filing does not specify whether proceeds will fund commercialization, research, debt reduction, or general corporate purposes. The business benefit is therefore financial flexibility rather than a change to FAYUVI’s clinical or commercial outlook.

The headline amount is not yet cash in hand. Closing remains conditional on customary requirements, including expiration or termination of the Hart-Scott-Rodino waiting period. 〔0〕 There is no published consensus benchmark for this type of asset sale; versus the standing expectation that the voucher could be monetized after FAYUVI approval, the new information is the agreed $203 million price and the path to cash realization.

Bottom line: This is a modestly positive financing event for Ultragenyx’s commercialization and pipeline effort, but it does not alter the core FAYUVI launch story. Its value is mainly the added non-dilutive cash, assuming the transaction closes.

What to watch next

PRV closing after HSR waiting period

Original filing on SEC EDGAR

More Ultragenyx Pharmaceutical Inc. news

Ultragenyx PRV sale adds $203M as FAYUVI launch begins | RARE Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.